New Clinical Model May Reduce Unnecessary Emergency Care for Pediatric Anaphylaxis

A validated prediction model can identify children with anaphylaxis who are at low risk for needing additional epinephrine after their initial prehospital dose, potentially sparing families from unnecessary emergency department (ED) visits. Published in *The Journal of Allergy and Clinical Immunology: In Practice* on June 24, the study suggests that children lacking specific risk factors—such as asthma or persistent symptoms—may be safely managed outside of an acute care setting, according to lead author Timothy E. Dribin, MD, of Cincinnati Children’s Hospital Medical Center.

Predicting the Need for Further Epinephrine

The research, a multicenter retrospective cohort study, analyzed 2,318 children who received a single dose of epinephrine before arriving at a hospital. By examining clinical data, researchers developed a model to predict which patients would require a second dose of epinephrine or additional interventions once they reached the ED or were admitted to inpatient care.

The model identified three primary pre-ED risk factors that signal a need for further medical attention:
* A documented history of asthma.
* Presence of cardiovascular symptoms prior to the initial epinephrine dose.
* Symptoms that were persistent, new, or recurrent after the initial dose but before arrival at the hospital.

When any of these factors were present in the external validation cohort, the model correctly identified 93% of patients who ultimately required additional epinephrine. Conversely, among patients the model classified as low risk, 95% did not require further doses.

Implications for Emergency Department Utilization

The findings suggest a potential shift in how pediatric anaphylaxis is managed. In the study cohort, 28% of encounters were classified as low risk by the model. Only 4.3% of these patients required additional epinephrine, indicating that a significant portion of pediatric anaphylaxis cases may not require the intensity of an ED visit if the patient remains stable.

The model demonstrated a high negative predictive value of 99%, effectively ruling out most patients who would have required life-saving interventions for refractory anaphylaxis. Dr. Dribin and his colleagues noted that these results support the safety of the 2023 Practice Parameter recommendations, which aim to refine clinical management of allergic reactions.

Study Limitations and Future Directions

While the model shows promise, the researchers noted several limitations. The study focused primarily on children with food-triggered anaphylaxis, meaning the findings may not apply to adults or patients experiencing reactions from non-food triggers, such as insect stings or medications. Additionally, the study used the administration of additional epinephrine as its primary outcome, a metric that can be influenced by varying clinical practices regarding the underuse of the medication.

The research team emphasized that the model requires prospective refinement and further validation before it becomes a standard tool in clinical practice. The study was supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health. Detailed disclosures for the authors, including consulting fees and research support, are available in the original publication.

Quick Summary: Factors for Clinical Assessment

| Risk Category | Clinical Indicators |
| :— | :— |
| Higher Risk | History of asthma, cardiovascular symptoms, or persistent/recurrent symptoms. |
| Lower Risk | Absence of the above factors following initial prehospital epinephrine. |

*Note: This article is for informational purposes and does not constitute medical advice. Always seek the guidance of a physician or other qualified health provider regarding any medical condition.*